Lead Clinical Therapy:

PSIL-006

The Highlights:

  • Neuroplastogens, such as PSIL-006, are engineered to promote neuroplasticity without the limitations of traditional psychedelics.

  • PSIL-006 is rapid-acting and has broad neuropsychiatric applications.

  • It is designed for patient-friendly, at-home oral dosing.

Targeted Indications

  • Depression

  • PTSD

  • Addiction- Focus: Alcohol Use Disorder (AUD)

  • Neurodegeneration- Focus: Frontotemporal Dementia (FTD)

Preclinical data show:

✓ Rapid Mood Benefits

✓ Reduces Impulsive Behaviors

✓ Improves Sleep

✓ Improves Working Memory

Clinical Trial Updates Coming Soon!